文献速递泌尿男性生殖肿瘤

立体定向消融放疗治疗原发性肾癌的长期结局(TROG 15.03 FASTRACK II):多中心、非随机、2期研究

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
PubMed 文献 · Lancet Oncol · 2026-05-17

FASTRACK II研究纳入70例医学上不可手术、高危或拒绝手术的原发性肾细胞癌患者,接受单次26 Gy或三次42 Gy的SABR,中位随访62个月,36、60、84个月局部控制率均为100%,未观察到局部复发或癌症相关死亡,长期安全性支持SABR用于非手术肾癌患者。

要点

  • SABR在36、60、84个月均达100%局部控制,无局部复发或癌症相关死亡。
  • 9个月内10%患者出现至少1次3级不良事件,无4级事件或治疗相关死亡。
  • 长期随访支持SABR用于医学上不可手术的原发性肾细胞癌患者。

核心结论

  • 长期随访支持SABR用于非手术肾细胞癌患者的安全性和局部控制,本队列未观察到局部复发或癌症相关死亡。

研究设计与样本

  • FASTRACK II为在澳大利亚和荷兰8家医院开展的非随机2期研究,纳入70例成人原发性肾细胞癌患者。
  • 患者接受单次26 Gy(肿瘤最大径≤4 cm)或三次42 Gy(肿瘤最大径>4 cm,间隔48小时)的SABR。
  • 主要终点为意向治疗人群的局部控制(RECIST评估),中位随访62个月(IQR 60-72)。

主要发现

  • SABR在36、60、84个月均达100%局部控制。
  • 9个月内7例(10%)患者出现至少1次3级不良事件:恶心呕吐3例(4%)、腹部/胁部/肿瘤疼痛4例(6%)、结肠梗阻2例(3%)、腹泻1例(1%)。
  • 未观察到新的长期安全性信号、4级事件或治疗相关死亡。

关键数值与推荐

  • 单次26 Gy用于肿瘤最大径≤4 cm,42 Gy分3次用于肿瘤最大径>4 cm。
  • 中位肿瘤大小46 mm(IQR 37-55),T1a 24例(34%)、T1b 39例(56%)、T2a 6例(9%)、T3a 1例(1%)。
  • 1例(1%)有淋巴结受累(N1)。

临床怎么用

  • 对于医学上不可手术、高危或拒绝手术的原发性肾细胞癌患者,SABR可作为非侵入性治疗选择。
  • 长期随访显示局部控制持续维持,需关注3级不良事件如恶心呕吐、疼痛、结肠梗阻和腹泻。

局限性

  • 非随机2期研究,样本量较小(70例),未收集种族和民族数据。
  • 研究人群以T1b疾病或更高分期为主,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging, non-invasive alternative for primary renal cell carcinoma. We aimed to provide the final long-term trial outcomes of TransTasman Radiation Oncology Group (TROG) 15.03 FASTRACK II, the first phase 2 trial investigating SABR for primary renal cell carcinoma to our knowledge. METHODS: FASTRACK II was a non-randomised, phase 2 study conducted in eight hospitals in Australia and the Netherlands by TROG and the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. Here, we report the final pre-planned follow-up results. Adult patients (aged ≥18 years) with histologically confirmed primary renal cell carcinoma, who were medically inoperable, high risk, or declined surgery, had an Eastern Cooperative Oncology Group performance status of 2 or less, had tumours 10 cm or less in size, and had N0-N1 disease were included. Patients underwent either a single fraction SABR of 26 Gy for tumours 4 cm or less in maximum diameter, or 42 Gy in three fractions delivered 48 h apart for tumours more than 4 cm in maximum diameter. The primary outcome was freedom from local progression to assess local control after SABR evaluated with the Response Evaluation Criteria in Solid Tumours. The primary endpoint and safety were evaluated in the intention-to-treat population. A patient representative was involved in the study design and conduct. The trial was registered with ClinicalTrials.gov (NCT02613819) and is closed to enrolment. FINDINGS: Between July 28, 2016, and Feb 27, 2020, 71 patients were enrolled and one withdrew consent before treatment. Median follow-up was 62 months (IQR 60-72), median age was 77 years (70-82). 49 (70%) of 70 patients were male and 21 (30%) were female. Race and ethnicity data were not collected. The median tumour size was 46 mm (37-55), with 24 (34%) patients with T1a disease, 39 (56%) with T1b disease, six (9%) with T2a disease, and one (1%) with T3a disease. One patient (1%) had nodal involvement (N1). SABR resulted in 100% local control at 36 months, 60 months, and 84 months. Seven (10%) patients had at least one grade 3 adverse event within 9 months of SABR that was designated possibly, probably, or definitely related to treatment: nausea and vomiting (three [4%] events); abdominal, flank, or tumour pain (four [6%]); colonic obstruction (two [3%]); and diarrhoea (one [1%]). No new long-term safety signals, grade 4 events, or treatment-related deaths were noted. INTERPRETATION: Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher. FUNDING: The Cancer Australia Priority-driven Collaborative Cancer Research Scheme and Varian.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Siva S, Pryor D, Martin J, et al. Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. Lancet Oncol. 2026. PMID: 42144018. doi:10.1016/S1470-2045(26)00091-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。